[1]CHOI J, KIM HJ, LEE J, et al. Risk of hepatocellular carcinoma in patients treated with entecavir vs tenofovir for chronic hepatitis B:A korean nationwide cohort study[J]. JAMA Oncol, 2018, 5 (1) :30-36.
|
[2]FLEMMING JA, TERRAULT NA. Tenofovir vs entecavir for hepatocellular carcinoma prevention in patients with chronic hepatitis B:One of these things is not like the other[J]. JAMA Oncol, 2018, 5 (1) :17-18.
|
[3]CHIEN J, LIU J, LEE MH, et al. Risk and predictors of hepatocellular carcinoma for chronic hepatitis B patients with newly developed cirrhosis[J]. J Gastroenterol Hepatol, 2016, 31 (12) :1971-1977.
|
[4]IDILMAN R, GUNSAR F, KORUK M, et al. Long-term entecavir or tenofovir disoproxil fumarate therapy in treatment-naive chronic hepatitis B patients in the real-world setting[J]. J Viral Hepat, 2015, 22 (5) :504-510.
|
[5]HAN Y, ZENG A, LIAO H, et al. The efficacy and safety comparison between tenofovir and entecavir in treatment of chronic hepatitis B and HBV related cirrhosis:A systematic review and Meta-analysis[J]. Int Immunopharmacol, 2017, 42:168-175.
|
[6]SATO A, OHTSUKI M, HATA M, et al. Antitumor activity of IFN-lambda in murine tumor models[J]. J Immunol, 2006, 176 (12) :7686-7694.
|
[7]LI K, LIU H, GUO T. Th17/Treg imbalance is an indicator of liver cirrhosis process and a risk factor for HCC occurrence in HBV patients[J]. Clin Res Hepatol Gastroenterol, 2017, 41 (4) :399-407.
|
[8]CLIFFORD RJ, ZHANG J, MEERZAMAN DM, et al. Genetic variations at loci involved in the immune response are risk factors for hepatocellular carcinoma[J]. Hepatology, 2010, 52 (6) :2034-2043.
|
[9]CHEN VL, LE AK, PODLAHA O, et al. Soluble intercellular adhesion molecule-1 is associated with hepatocellular carcinoma risk:Multiplex analysis of serum markers[J]. Sci Rep, 2017, 7 (1) :11169.
|
[10]ZEKRI AN, EL DEEB S, BAHNASSY AA, et al. Role of relevant immune-modulators and cytokines in hepatocellular carcinoma and premalignant hepatic lesions[J]. World J Gastroenterol, 2018, 24 (11) :1228-1238.
|
[11]ZAMOR PJ, DELEMOS AS, RUSSO MW. Viral hepatitis and hepatocellular carcinoma:Etiology and management[J]. J Gastrointest Oncol, 2017, 8 (2) :229-242.
|
[12]TAN A, GAO Y, YAO Z, et al. Genetic variants in IL12 influence both hepatitis B virus clearance and HBV-related hepatocellular carcinoma development in a Chinese male population[J]. Tumour Biol, 2016, 37 (5) :6343-6348.
|
[13]SHIN JW, JUNG SW, LEE SB, et al. Medication nonadherence increases hepatocellular carcinoma, cirrhotic complications, and mortality in chronic hepatitis B patients treated with entecavir[J]. Am J Gastroenterol, 2018, 113 (7) :998-1008.
|
[14]CHOI MS, SINN DH, KIM SA, et al. The clinical and laboratory characteristics of patients with chronic hepatitis B using current or past antiviral therapy in Korea:A multi-center, nation-wide, cross-sectional epidemiologic study[J]. Gut Liver, 2012, 6 (2) :241-248.
|
[15]ZHANG W, WANG X, WANG Y, et al. Effective viral suppression is necessary to reduce hepatocellular carcinoma development in cirrhotic patients with chronic hepatitis B:Results of a10-year follow up[J]. Medicine (Baltimore) , 2017, 96 (44) :e8454.
|
[16]WU IT, HU TH, HUNG CH, et al. Comparison of the efficacy and safety of entecavir and tenofovir in nucleos (t) ide analogue-na6ve chronic hepatitis B patients with high viremia:A retrospective cohort study[J]Clin Microbiol Infect, 2017, 23 (7) :464-469.
|
[17]HOU JL, ZHAO W, LEE CH, et al. Prospective, randomized safety assessment of long-term therapy with entecavir or other agents in patients with chronic HBV infection[R]. AASLD Annual Meeting, 2017.
|